|
nasdaq:tgtx
|
2816181
|
Apr 21st, 2024 12:00AM
|
TG Therapeutics, Inc.
|
23K
|
348.00
|
Open
|
|
Apr 21st, 2024 03:21AM
|
Apr 21st, 2024 03:21AM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 20th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
23K
|
348.00
|
Open
|
|
Apr 20th, 2024 12:11AM
|
Apr 20th, 2024 05:43PM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 19th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
23K
|
347.00
|
Open
|
|
Apr 19th, 2024 04:44AM
|
Apr 19th, 2024 04:44AM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 18th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
23K
|
344.00
|
Open
|
|
Apr 18th, 2024 01:08AM
|
Apr 18th, 2024 07:04PM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 17th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
22K
|
344.00
|
Open
|
|
Apr 17th, 2024 04:15AM
|
Apr 17th, 2024 03:30PM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 16th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
22K
|
344.00
|
Open
|
|
Apr 16th, 2024 12:03AM
|
Apr 16th, 2024 11:46AM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 15th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
22K
|
344.00
|
Open
|
|
Apr 14th, 2024 11:59PM
|
Apr 15th, 2024 05:27PM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 14th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
22K
|
343.00
|
Open
|
|
Apr 13th, 2024 11:47PM
|
Apr 13th, 2024 11:47PM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 13th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
22K
|
343.00
|
Open
|
|
Apr 12th, 2024 11:39PM
|
Apr 13th, 2024 12:12PM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tgtx
|
2816181
|
Apr 12th, 2024 12:00AM
|
TG Therapeutics, Inc.
|
22K
|
342.00
|
Open
|
|
Apr 11th, 2024 11:46PM
|
Apr 12th, 2024 09:08AM
|
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).
|
Open
|
Biotechnology, hematological malignancies, non-Hodgkin's lymphoma, multiple sclerosis, b-cell diseases, ublituximab, and umbralisib
|
Open
|
|
New York
|
NY
|
US
|
10014
|
|
TG Therapeutics
|
|
Pharmaceuticals & Biotechnology
|